PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-109.95%
Negative EBIT growth while AXSM is at 23.84%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
62.96%
Operating income growth above 1.5x AXSM's 35.57%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
53.00%
Net income growth above 1.5x AXSM's 19.26%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
52.84%
EPS growth above 1.5x AXSM's 20.49%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
52.84%
Diluted EPS growth above 1.5x AXSM's 20.49%. David Dodd would see if there's a robust moat protecting these shareholder gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
18.82%
OCF growth at 50-75% of AXSM's 25.25%. Martin Whitman would question if the firm lags in monetizing sales effectively.
18.82%
FCF growth 50-75% of AXSM's 25.25%. Martin Whitman would see if structural disadvantages exist in generating free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-253.14%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-253.14%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-34.55%
Negative 3Y OCF/share CAGR while AXSM stands at 23.58%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-2662.04%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-2662.04%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
63.01%
3Y net income/share CAGR above 1.5x AXSM's 11.48%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
-1507.60%
Negative equity/share CAGR over 10 years while AXSM stands at 360.64%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-1507.60%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-84.19%
Negative 3Y equity/share growth while AXSM is at 280.02%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.23%
We have a declining book value while AXSM shows 35.76%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-65.79%
We cut SG&A while AXSM invests at 7.86%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.